Lung Cancer
Volume 64, Issue 2 , Pages 219-225, May 2009

VEGF, TNF-α and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer

Respiratory Medicine Department, University of Thessaly Medical School, University Hospital of Larissa, Larissa 41110, Greece

Received 16 June 2008; received in revised form 21 August 2008; accepted 29 August 2008. published online 10 October 2008.

Abstract 

The aim of the present study was to evaluate the levels of VEGF, 8-isoprostane and TNF-α in EBC and serum of patients with primary lung cancer prior to the initiation of any treatment, in order to evaluate their possible diagnostic role. Furthermore, associations between VEGF, 8-isoprostane and TNF-α levels in EBC and serum with clinicopathologic factors were investigated.

We enrolled 30 patients with lung cancer (mean age 65.2±10.5 years) and 15 age and gender-matched healthy smokers as controls. Serum and EBC were collected before any treatment. TNF-α, VEGF and 8-isoprostane levels in EBC and serum were analyzed by an immunoenzymatic method (ELISA).

A statistically significant difference was observed between lung cancer patients and the control group regarding the values of TNF-α, both in EBC (52.9±5.0pg/ml vs. 19.4±3.9pg/ml, p<0.0001) and serum (44.5±6.3pg/ml vs. 22.2±4.3pg/ml, p=0.035). Moreover, EBC VEGF levels were higher in patients with T3–T4 tumor stage compared to T1–T2 (9.3±2.8pg/ml vs. 2.3±0.7pg/ml, p=0.047). A statistically significant correlation was also observed between serum and EBC values of VEGF (r=0.52, p=0.019). In addition, serum levels of VEGF were higher in lung cancer patients than in controls (369.3±55.1pg/ml vs. 180.5±14.7pg/ml, p=0.046). VEGF serum levels were also found higher in patients with advanced stage of disease (IIIB–IV) and distant nodal metastasis (N2–N3). No differences were observed in 8-isoprostane in EBC between lung cancer patients and controls. In contrast, serum 8-isoprostane levels were higher in lung cancer patients compared to controls (24.9±3.6pg/ml vs. 12.9±1.6pg/ml, p=0.027) and were higher in patients with advanced disease. All three biomarkers presented acceptable reproducibility in the EBC on two consecutive days.

In conclusion, we have shown that TNF-α, VEGF and 8-isoprostane are elevated in the serum of lung cancer patients and increased serum VEGF and 8-isoprostane levels are related to advanced disease. In EBC, increased TNF-α levels were observed in lung cancer patients, whereas increased VEGF levels were observed in advanced T-stage. Further longitudinal studies are warranted for the evaluation of the prognostic role of these biomarkers in lung cancer.

Abbreviations: EBC, exhaled breath condensate, VEGF, vascular endothelial growth factor, TNF-α, tumor necrosis factor alpha, ROS, reactive oxygen species, BAL, bronchoalveolar lavage

Keywords: TNF-α, VEGF, 8-Isoprostane, Oxidative stress, Biomarkers, Exhaled breath condensate, Lung cancer

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0169-5002(08)00461-3

doi:10.1016/j.lungcan.2008.08.015

Lung Cancer
Volume 64, Issue 2 , Pages 219-225, May 2009